Issue: Volume XX No. 3 - March 4, 2013

Leveraging Testing Technology To Identify MRSA, C. Difficile

CEO SUMMARY: Probably the most challenging infections for hospitals to control and reduce are methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). The laboratory at one New York hospital introduced algorithms to screen for the presence of each infection. In the past five years, the hospital not only cut costs by almost $3 million …

Leveraging Testing Technology To Identify MRSA, C. Difficile Read More »

Predicting the End of Fee-for-Service Medicine

HOW DISRUPTIVE WILL THE END OF FEE-FOR-SERVICE MEDICINE be to the lab testing industry? I ask this question because we are about to leave the era of fee-for-service (FFS) medicine and move into the era of value-based and bundled reimbursement. Since World War II, FFS has been the overwhelmingly dominant payment model for the healthcare …

Predicting the End of Fee-for-Service Medicine Read More »

Urologists Weigh in on Prostate Biopsy Testing

CEO SUMMARY: Based on an impressive number of 4,230,129 vials collected from 437,937 biopsies, the new study is expected to add fuel to the fire of the ongoing debate about the appropriate number of prostate biopsies physicians should collect and refer to pathology labs for cancer testing. The researchers compared the number of prostate biopsies …

Urologists Weigh in on Prostate Biopsy Testing Read More »

Palmetto’s Prostate Biopsy Policy Removed after Talks with CMS

THERE IS SOME POSITIVE LAB INDUSTRY NEWS that has not been widely reported yet. It involves a decision to change an unwelcome Medicare policy that limited the number of prostate biopsy specimens per case that would be reimbursed. After discussions between lab industry groups and the federal Centers for Medicare & Medicaid Services (CMS), Palmetto …

Palmetto’s Prostate Biopsy Policy Removed after Talks with CMS Read More »

Two MTs Launch New Lab In Aberdeen, North Carolina

CEO SUMMARY: Although located in the same region as two of the nation’s largest laboratory companies, newly-created Triune Laboratory, Inc., is reporting steady growth and acceptance by physicians in the community. Founded by two medical technologists and partially funded by a pathologist, this new lab company demonstrates that many physicians are ready to support an …

Two MTs Launch New Lab In Aberdeen, North Carolina Read More »

LipoScience Completes IPO, Raises $44.9 Million from Sale

IT HAS BEEN A WHILE since a laboratory company has successfully completed an initial public offering (IPO). Thus, it is notable that LipoScience Inc., of Raleigh, North Carolina, recently accomplished that feat. On January 24, 2013, Liposcience closed its IPO and raised $44.9 million. It now trades on NASDAQ under the stock symbol LPDX. The …

LipoScience Completes IPO, Raises $44.9 Million from Sale Read More »

EHR Donation Ruling in WA Raises Questions for Labs

CEO SUMMARY: When the Washington State Attorney General issued an Attorney General Opinion last fall, he created confusion among pathologists and lab directors whose labs have paid to have EHR software installed in physicians’ offices. The Washington AG’s ruling not only conflicts with federal law, which allows labs to donate EHR software, but raises questions …

EHR Donation Ruling in WA Raises Questions for Labs Read More »

Dark Daily

March 4, 2013 “Intelligence: Late-Breaking Lab News”

Even if not billion-dollar transactions, there are some interesting deals unfolding in the in vitro diagnostics (IVD) marketplace. Last month, HYCOR Biomedical, Inc., of Garden Grove, California, sold its Kova urinalysis system and business “to an affiliate of One Rock Capital Partners, Laurel Crown Partners, and StoneCreek Capital,” according to a Hycor press release. As …

March 4, 2013 “Intelligence: Late-Breaking Lab News” Read More »

Powered by Americaneagle.com

Hosted by Americaneagle.com, Inc.